Electra aims for nearly $300M IPO; Enhertu's Phase 3 lung cancer success
Plus news about Lilly, Cellectis, Tyra, Shennon and QL Biopharm. Electra Therapeutics eyes $297M IPO: The Sanofi-backed biotech hopes to kick off the post-Labor Day IPO train with a nearly $300 million ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
